Hormone replacement therapy effectiveness and safety in postmenopausal women with metabolic syndrome
Aim. То compare the effects of hormone replacement therapy (HRT) and antihypertensive therapy (AHT) on metabolic profile, insulin resistance (IR) and central hemodynamics in postmenopausal women with metabolic syndrome (MS).Material and methods. In total, 46 postmenopausal women with MS were examine...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2009-02-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/1160 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849250710426746880 |
|---|---|
| author | O. N. Poryvkina T. V. Ardasheva V. S. Zadionchenko M. A. Lipatova A. E. Pikhlak O. I. Pososhkova I. A. Logacheva |
| author_facet | O. N. Poryvkina T. V. Ardasheva V. S. Zadionchenko M. A. Lipatova A. E. Pikhlak O. I. Pososhkova I. A. Logacheva |
| author_sort | O. N. Poryvkina |
| collection | DOAJ |
| description | Aim. То compare the effects of hormone replacement therapy (HRT) and antihypertensive therapy (AHT) on metabolic profile, insulin resistance (IR) and central hemodynamics in postmenopausal women with metabolic syndrome (MS).Material and methods. In total, 46 postmenopausal women with MS were examined. Group I (n=30) received estradiol (1 mg/day) and drospirenone (2 mg/day) for 6 months (Angeliq medication). Group II (n=16) received various antihypertensive medications. At baseline and after 6 months of the treatment, lipid profile, glycemia and insulinemia, IR index HOMA-IR, body composition, Kuperman index (modified by E..M. Vikhlyaeva) were assessed, 24-hour blood pressure monitoring (BPM) and echocardiography were performed.Results. In Group I, body mass index (BMI) reduced from 30,9 kg/m2 to 30,2 kg/m2 (p=0,068); in Group II, it increased from 30,6 kg/m2to 31,3 kg/m2 (p=0,003). Visceral fat tissue percentage was 40,6 %. at baseline and 42,2 % after 6 months in Group I, comparing to 41,0 % and 42,2 %, respectively, in Group II (p=0,018). Angeliq medication demonstrated good antihypertensive activity. In Group I, left ventricular myocardial mass index (LVMMI) significantly reduced from 116,1 g/m2 to 110,8 g/m2 (p<0,0001); in Group II, it decreased from 116,4 g/m2 to 112,7 g/m2 only (p=0,062). HRT did not affect metabolic profile.Conclusion. Angeliq medication was effective and safe in women with high cardiovascular risk, with no adverse effect on metabolic profile or IR. Due to its anti-mineralocorticoid action, Angeliq improved central hemodynamics parameters and reduced BR. |
| format | Article |
| id | doaj-art-bbf1bb5b2ce24cd4866681b1c6bdb22b |
| institution | Kabale University |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| publishDate | 2009-02-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj-art-bbf1bb5b2ce24cd4866681b1c6bdb22b2025-08-20T03:57:09Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252009-02-01817580872Hormone replacement therapy effectiveness and safety in postmenopausal women with metabolic syndromeO. N. Poryvkina0T. V. Ardasheva1V. S. Zadionchenko2M. A. Lipatova3A. E. Pikhlak4O. I. Pososhkova5I. A. Logacheva6Moscow State Medico-Stomatological University, City Clinical Hospital No. 11Moscow State Medico-Stomatological University, City Clinical Hospital No. 11Moscow State Medico-Stomatological University, City Clinical Hospital No. 11Moscow City Healthcare DepartmentMoscow State Medico-Stomatological University, City Clinical Hospital No. 11Moscow State Medico-Stomatological University, City Clinical Hospital No. 11Moscow State Medico-Stomatological University, City Clinical Hospital No. 11Aim. То compare the effects of hormone replacement therapy (HRT) and antihypertensive therapy (AHT) on metabolic profile, insulin resistance (IR) and central hemodynamics in postmenopausal women with metabolic syndrome (MS).Material and methods. In total, 46 postmenopausal women with MS were examined. Group I (n=30) received estradiol (1 mg/day) and drospirenone (2 mg/day) for 6 months (Angeliq medication). Group II (n=16) received various antihypertensive medications. At baseline and after 6 months of the treatment, lipid profile, glycemia and insulinemia, IR index HOMA-IR, body composition, Kuperman index (modified by E..M. Vikhlyaeva) were assessed, 24-hour blood pressure monitoring (BPM) and echocardiography were performed.Results. In Group I, body mass index (BMI) reduced from 30,9 kg/m2 to 30,2 kg/m2 (p=0,068); in Group II, it increased from 30,6 kg/m2to 31,3 kg/m2 (p=0,003). Visceral fat tissue percentage was 40,6 %. at baseline and 42,2 % after 6 months in Group I, comparing to 41,0 % and 42,2 %, respectively, in Group II (p=0,018). Angeliq medication demonstrated good antihypertensive activity. In Group I, left ventricular myocardial mass index (LVMMI) significantly reduced from 116,1 g/m2 to 110,8 g/m2 (p<0,0001); in Group II, it decreased from 116,4 g/m2 to 112,7 g/m2 only (p=0,062). HRT did not affect metabolic profile.Conclusion. Angeliq medication was effective and safe in women with high cardiovascular risk, with no adverse effect on metabolic profile or IR. Due to its anti-mineralocorticoid action, Angeliq improved central hemodynamics parameters and reduced BR.https://cardiovascular.elpub.ru/jour/article/view/1160metabolic syndromepost-menopausehormone replacement therapyobesityinsulin resistance |
| spellingShingle | O. N. Poryvkina T. V. Ardasheva V. S. Zadionchenko M. A. Lipatova A. E. Pikhlak O. I. Pososhkova I. A. Logacheva Hormone replacement therapy effectiveness and safety in postmenopausal women with metabolic syndrome Кардиоваскулярная терапия и профилактика metabolic syndrome post-menopause hormone replacement therapy obesity insulin resistance |
| title | Hormone replacement therapy effectiveness and safety in postmenopausal women with metabolic syndrome |
| title_full | Hormone replacement therapy effectiveness and safety in postmenopausal women with metabolic syndrome |
| title_fullStr | Hormone replacement therapy effectiveness and safety in postmenopausal women with metabolic syndrome |
| title_full_unstemmed | Hormone replacement therapy effectiveness and safety in postmenopausal women with metabolic syndrome |
| title_short | Hormone replacement therapy effectiveness and safety in postmenopausal women with metabolic syndrome |
| title_sort | hormone replacement therapy effectiveness and safety in postmenopausal women with metabolic syndrome |
| topic | metabolic syndrome post-menopause hormone replacement therapy obesity insulin resistance |
| url | https://cardiovascular.elpub.ru/jour/article/view/1160 |
| work_keys_str_mv | AT onporyvkina hormonereplacementtherapyeffectivenessandsafetyinpostmenopausalwomenwithmetabolicsyndrome AT tvardasheva hormonereplacementtherapyeffectivenessandsafetyinpostmenopausalwomenwithmetabolicsyndrome AT vszadionchenko hormonereplacementtherapyeffectivenessandsafetyinpostmenopausalwomenwithmetabolicsyndrome AT malipatova hormonereplacementtherapyeffectivenessandsafetyinpostmenopausalwomenwithmetabolicsyndrome AT aepikhlak hormonereplacementtherapyeffectivenessandsafetyinpostmenopausalwomenwithmetabolicsyndrome AT oipososhkova hormonereplacementtherapyeffectivenessandsafetyinpostmenopausalwomenwithmetabolicsyndrome AT ialogacheva hormonereplacementtherapyeffectivenessandsafetyinpostmenopausalwomenwithmetabolicsyndrome |